The product is available in 100 mg and 40 mg strengths, priced at Rs 28,950 and Rs 13,950 respectively. The company said the prices are approximately one-fourth of the reference drug.
According to the company, the lower pricing is expected to improve affordability and reduce the overall cost of immunotherapy, with potential benefits for more than 5 lakh patients. The availability of two dosage strengths is intended to help clinicians optimise dosing and minimise drug wastage, which is a key cost factor in immuno-oncology treatments.
Zydus stated that Tishtha has been developed and manufactured in India, with an emphasis on ensuring consistent and long-term availability for patients who require therapy over multiple treatment cycles. The company highlighted affordability, consistency of supply, and reach as critical factors influencing access to modern cancer therapies.
Zydus Lifesciences is a global life sciences company with operations across pharmaceuticals, consumer wellness, and medical technology. It posted a 38.12% YoY rise in consolidated net profit to Rs 1,258.6 crore in Q2 FY26, while revenue grew 18.07% to Rs 6,037.9 crore.